Lysosomal Storage Disorder Therapeutics Pipeline Analysis 2017

  • ID: 4340314
  • Report
  • 222 pages
  • P&S Market Research
1 of 3
Disease Overview

Lysosomal storage disorder refers to inherited metabolic disorders that are characterize by enzyme deficiencies, which results in an abnormal build-up of various toxic materials in the body's cells. There are nearly 50 types of lysosomal storage disorder which affect various parts of the body including the brain, skeleton, heart, central nervous system and skin. Some of the lysosomal storage disorders are Aspartylglucosaminuria, Batten Disease, Cystinosis, Fabry Disease, Glycogen Storage Disease II (Pompe Disease), GM2-Gangliosidosis Type I (Tay Sachs Disease), GM2-Gangliosidosis Type II (Sandhoff Disease), Metachromatic Leukodystrophy, Gaucher’s Disease Types I, II, and III, Mucolipidosis Types I, II/III and IV, Mucopolysaccharide Storage Diseases (Hurler Disease and variants, Hunter, Sanfilippo Types A,B,C,D, Morquio Types A and B, Maroteaux-Lamy and Sly diseases), Niemann-Pick Disease Types A/B, C1 and C2 and Schindler Disease Types I and II.

The signs and symptoms vary for different diseases, according to the enzyme deficiency for this group of diseases. Some of the symptoms associated with lysosomal storage disorder include enlargement of the liver (hepatomegaly), rapidly progressive vision failure (optic atrophy), impaired kidney function, burning pain in the hands and feet, chronic fatigue, lethargy, mild mental retardation and abnormalities of the face and skull. Lysosomal storage disorder can be treated by bone marrow transplantation and enzyme replacement therapy (ERT). Some of the marketed drugs for lysosomal storage disorder include alglucerase injection (Ceredase), for treatment of Gaucher’s disease type I; miglustat (Zavesca) for treatment of Gaucher’s disease type I; Fabrazyme, for treatment of Fabry disease and Aldurazyme for treatment for Mucopolysaccharide Type I.

Drug manufacturing companies are constantly involved in the quest to find better and new treatment strategies with potential enzyme replacement therapies such as N-acetylglucosaminidase alpha (NAGLU) replacement which can also prove to be effective in Sanfilippo syndrome type B treatment. Various companies are developing drug candidates using different technologies for the development of effective and better drugs, which is driving the growth of the pipeline.

As of June 2017, the lysosomal storage disorder therapeutics pipeline comprised of approximately 74 drug candidates in different stages of development. The figure below depicts the number of drug candidates and their phases.

Lysosomal Storage Disorders Pipeline Analysis

Competitive Landscape

Some of the other key players developing drugs for the treatment of lysosome storage disorder include GlaxoSmithKline plc, Sanofi Genzyme, Amicus Therapeutics, Inc. and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
  • Market Forecast - Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Lysosomal Storage Disorder Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Route Of Administration
4.4.3 Pipeline Analysis By Molecule Type
4.4.4 Pipeline Analysis By Company

5. Lysosomal Storage Disorder Therapeutics Pipeline Analysis By Phase (2017)
5.1 Filed: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Iii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase Ii: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Phase I: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Clinical Trials
5.4.4 Clinical Results
5.4.5 Strategic Development
5.4.6 Designation
5.4.7 Grants
5.4.8 Patent
5.4.9 Technology
5.5 Pre-Clinical: Drug Profiles
5.5.1 Pre-Clinical Study
5.5.2 Pre-Clinical Results
5.5.3 Strategic Development
5.5.4 Designation
5.5.5 Grants
5.5.6 Patent
5.5.7 Technology
5.6 Discovery: Drug Profiles
5.6.1 Strategic Development
5.6.2 Designation
5.6.3 Grants
5.6.4 Patent
5.6.5 Technology

6 Competitive Landscape
6.1 Key Players Benchmarking For Lysosomal Storage Disorder Therapeutic Candidates
6.2 Swot Analysis Of Lysosomal Storage Disorder Therapeutics Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Lysosomal Storage Disorder, By Company (2017)
Description Of Filed Drug Candidates
Clinical Trials Of Filed Drug Candidates
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Companies- At A Glance

List Of Figures
Research Methodology For The Lysosomal Storage Disorder Therapeutics Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents By Industry Participant
Breakdown Of Primary Research Respondents By Company Type
Number Of Lysosomal Storage Disorder Therapeutics Under Development (2017)
Lysosomal Storage Disorder Therapeutics Pipeline Split, By Route Of Administration (2017)
Lysosomal Storage Disorder Therapeutics Pipeline Split, By Molecule Type (2017)
Key Players Benchmarking For Lysosomal Storage Disorder Therapeutic Candidates
Swot Analysis Of Lysosomal Storage Disorder Therapeutics Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll